Mark D. Black
Affiliations: | sanofi-aventis.com, St. Louis, MO, United States |
Area:
NeuroscienceGoogle:
"Mark Black"Mean distance: 18.82 (cluster 17)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Griebel G, Pichat P, Boulay D, et al. (2016) The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia. Scientific Reports. 6: 35320 |
| Naimoli V, Featherstone R, Potestio L, et al. (2015) Compound A, a novel, potent and selective mGluR2 positive allosteric modulator: III. Effects in clinically relevant translational cognition models that could be used as biomarkers F1000research. 4 |
| Griebel G, Pichat P, Pruniaux MP, et al. (2012) SAR110894, a potent histamine H₃-receptor antagonist, displays procognitive effects in rodents. Pharmacology, Biochemistry, and Behavior. 102: 203-14 |
| Black MD, Stevens RJ, Rogacki N, et al. (2011) AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology. 215: 149-63 |
| Liang G, Neuenschwander K, Chen X, et al. (2011) Structure-based design, synthesis, and profiling of potent and selective neuronal nitric oxide synthase (nNOS) inhibitors with an amidinothiophene hydroxypiperidine scaffold Medchemcomm. 2: 201-205 |
| Barak S, Arad M, De Levie A, et al. (2009) Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 34: 1753-63 |
| Black MD, Varty GB, Arad M, et al. (2009) Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology. 202: 385-96 |
| Black MD. (2005) Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. Psychopharmacology. 179: 154-63 |
| Black MD, Simmonds J, Senyah Y, et al. (2002) Neonatal nitric oxide synthase inhibition: social interaction deficits in adulthood and reversal by antipsychotic drugs. Neuropharmacology. 42: 414-20 |
| Black MD, Wotanis J, Schilp DE, et al. (2000) Effect of AMPA receptor modulators on hippocampal and cortical function. European Journal of Pharmacology. 394: 85-90 |